The history of Sildenafil presents a complex case for stakeholders in the drug sector. While initially a blockbuster success, producing huge profits, the intellectual property expiration and the subsequent flood of cheaper alternatives have considerably changed revenue. This raises questions about the ongoing profitability of analogous medication i